Comparison of the stimulus properties of a pre- vs. a putative postsynaptic dose of quinpirole

Pharmacology, Biochemistry, and Behavior
D A Cory-SlechtaR A Fox

Abstract

Presynaptic D2-like receptors appear to mediate the stimulus properties of a low dose (0.05 mg/kg) of the D2-like agonist quinpirole (QUIN), because treatments decreasing dopamine (DA) release or blocking postsynaptic DA receptor activation produce QUIN-appropriate responding in a drug discrimination context, whereas treatments activating postsynaptic DA receptors evoke saline responding (28). This study examined the hypothesis that training to a presumably postsynaptic dose of QUIN (0.20 mg/kg) would produce the opposite pattern of effects. Using drug discrimination procedures, substitution for 0.05 mg/kg (28), but not 0.20 mg/kg QUIN, was produced by the D1 antagonist SCH23390, the catecholamine depleter alpha-methyl-paratyrosine and low doses of apomorphine (up to 0.25 mg/kg). The D2 agonist NPA substituted fully for 0.05 but only partially for 0.20 mg/kg QUIN. Cocaine and d-amphetamine (alone or with SCH 23390) substituted only minimally for either QUIN training dose. The putative D3 agonist 7-OH-DPAT engendered primarily saline responding when substituted for 0.20 QUIN. The 0.20 QUIN stimulus was antagonized by the D2 blocker haloperidol and partially blocked by the D1 antagonist SCH 23390. These data show a clear differen...Continue Reading

References

Feb 11, 1992·European Journal of Pharmacology·D R GehlertJ Schaus
Sep 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·D LévesqueP Sokoloff
Oct 2, 1991·European Journal of Pharmacology·P Seeman, J M Schaus
Aug 14, 1991·European Journal of Pharmacology·O CivelliH H Van Tol
May 1, 1990·Behavioral and Neural Biology·J E WilliamsW L Woolverton
Feb 28, 1989·European Journal of Pharmacology·D Eilam, H Szechtman
May 1, 1988·Pharmacology, Biochemistry, and Behavior·F J WhiteR J Brooderson
Jan 1, 1987·Psychopharmacology·A H Tang, S R Franklin
Apr 1, 1985·Toxicology and Applied Pharmacology·D A Cory-SlechtaC Cox
Jun 1, 1994·Pharmacology, Biochemistry, and Behavior·J F McElroy
Jul 1, 1994·Trends in Pharmacological Sciences·P Seeman, H H Van Tol

❮ Previous
Next ❯

Citations

Apr 28, 2001·Pharmacology, Biochemistry, and Behavior·C L Zuch, D A Cory-Slechta
Jul 23, 2003·Pharmacology, Biochemistry, and Behavior·Charles D Cook, Patrick M Beardsley
Jul 27, 1999·Pharmacology, Biochemistry, and Behavior·B J Brockel, D A Cory-Slechta
Apr 7, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mireille BasselinStanley I Rapoport
Jan 4, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Bojana Zupan, Miklos Toth
Dec 26, 2007·Brain Research Bulletin·Andras HajnalMihai Covasa
May 9, 2006·Behavioural Brain Research·Davide AmatoPaolo Nencini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here